Nerve growth factor - Sinobioway Bio-medicine

Drug Profile

Nerve growth factor - Sinobioway Bio-medicine

Latest Information Update: 16 Mar 2017

Price : $50

At a glance

  • Originator Xiamen Bioway Biotech
  • Developer Sinobioway Bio-medicine
  • Class Nerve growth factors; Neuroprotectants
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Optic nerve disorders
  • Clinical Phase Unknown Brain disorders
  • No development reported Spinal muscular atrophy

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Spinal-muscular-atrophy(In children) in China (Parenteral, Injection)
  • 15 Sep 2013 Clinical trials in Brain disorders (in infants) in China (parenteral)
  • 01 Oct 2010 Phase-I clinical trials in Spinal muscular atrophy in China (parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top